Clinical trials recruiting in Donostia / San Sebastian, Spain

Phase breakdown

Conditions recruiting in Donostia / San Sebastian, Spain

Recruiting trials in Donostia / San Sebastian, Spain

• A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
  NCT07647328 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
  NCT04929223 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
  NCT06686615 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
  NCT06926868 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
  NCT07174336 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07169578 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
  NCT07174310 · Phase: Phase 3 · Ages: 50 Years to 85 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
  NCT06976203 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female)
• ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
  NCT04889924 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
  NCT07207811 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
  NCT03605771 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
  NCT03567889 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
  NCT06887088 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Immunological Characteristics of Preclinical IBD
  NCT05698745 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
  NCT07234695 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female)
• PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
  NCT04477785 · Phase: Not specified · Ages: 30 Years and older · Sex: All (male and female)
• Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies
  NCT06459648 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
  NCT05855200 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• The European NAFLD Registry
  NCT04442334 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female)
• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
  NCT05950945 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Donostia / San Sebastian, Spain?

21 recruiting trials have at least one study site in Donostia / San Sebastian, Spain.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.